This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen A. Fausti, PhD; James A. Henry, MS; Heidi I. Schaffer, MA; Deanna J. Olson, MS; Richard H. Frey; Grover C. Bagby, Jr, MD

Arch Otolaryngol Head Neck Surg. 1993;119(6):661-666.

Abstract
• Cisplatin can cause irreversible hearing loss initially detectable as impairment of high-frequency hearing with progression to lower frequencies. Many patients receiving cisplatin are too ill to tolerate lengthy audiometric testing. Therefore, a rapid and sensitive high-frequency monitoring strategy to detect cisplatin-induced ototoxicity is needed. Serial conventional (0.25 to 8 kHz) and high-frequency (8 kHz) threshold monitoring was performed in patients receiving cisplatin, resulting in 84% of ears showing hearing loss, of which 71% were detected first in frequencies of 8 kHz or greater. By analysis according to an individualized, specific high-frequency range, early identification of hearing loss occurred in 94% of ears showing change. This five-frequency procedure is a sensitive detector of ototoxicity and is proposed as an alternative monitoring protocol for patients receiving cisplatin who cannot tolerate extended testing.

(Arch Otolaryngol Head Neck Surg. 1993;119:661-666)

Author Affiliations
From the Department of Veterans Affairs (Dr Fausti), the Auditory Research Laboratory (Messrs Henry and Frey and Mss Schaffer and Olson), and the Hematology/Oncology Service (Dr Bagby), Portland (Ore) Veterans Affairs Medical Center; and the Department of Otolaryngology (Dr Fausti) and the Division of Hematology and Medical Oncology Service (Dr Bagby), Oregon Health Sciences University, Portland.

Footnotes
Accepted for publication December 15, 1992.

Presented in part at the American Academy of Audiology Annual Convention, Denver, Colo, April 28, 1991.

Reprint requests to Portland Veterans Affairs Medical Center (151J), PO Box 1034, Portland, OR 97207 (Dr Fausti).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry
Borba et al.
Lupus 2004;13:223-227.
ABSTRACT